Yes, Assertio Therapeutics (operating as Assertio Holdings, Inc.) has actively expanded its commercial portfolio and pharmaceutical asset base through strategic mergers, licensing deals, and corporate acquisitions. A notable example includes its acquisition of Spectrum Pharmaceuticals, which brought commercial-stage oncology assets under Assertio's corporate umbrella. These business development initiatives have historically allowed the company to diversify its product lines across neurology, pain management, and oncology supportive care therapies.